News Astellas' Iveric takeover rewarded with FDA nod for GA drug The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company
News Astellas cuts $5.9bn deal to buy Iveric Bio Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
